Ursula Wiedermann - Imugene Chief Scientific Officer
Executive
Prof. Dr. Ursula Wiedermann was appointed as Chief Scientific Officer of Imugene Ltd., with effect from 5 June 2015. Prof Dr Wiedermann has worked as the Principal Investigator for the preclinical development of HERVaxx alongside Professor Christophe Zielinski, and currently serves on the Companys scientific advisory board. Together they performed the Phase I Clinical trial of HERVaxx in metastatic breast cancer patients. Prof Dr Wiedermann is the Professor of Vaccinology at the Medical University of Vienna, one of the oldest and largest medical campuses in Europe. She has a distinguished scientific career with a particular interest in immunology and vaccines, has over 110 publications in peer reviewed scientific journals to her credit and is a frequent speaker at international conferences. since 2015.
| Tenure | 9 years |
| Phone | 61 3 9824 5254 |
| Web | https://www.imugene.com |
Imugene Management Efficiency
The company has return on total asset (ROA) of (0.2148) % which means that it has lost $0.2148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3718) %, meaning that it generated substantial loss on money invested by shareholders. Imugene's management efficiency ratios could be used to measure how well Imugene manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 673.43 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Imugene Limited has a current ratio of 15.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Imugene until it has trouble settling it off, either with new capital or with free cash flow. So, Imugene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imugene Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imugene to invest in growth at high rates of return. When we think about Imugene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gopal MBBS | Rezolute | N/A | |
| Jiang JD | Connect Biopharma Holdings | N/A | |
| Weiying Zhu | Instil Bio | N/A | |
| Laetitia Hupman | Instil Bio | N/A | |
| Sekhar Bhattacharjee | Instil Bio | 52 | |
| Sumit Biswas | Instil Bio | 52 | |
| Colleen Sjogren | Nuvation Bio | N/A | |
| Alan Smith | Nutriband | 58 | |
| Clayton Delmarter | Instil Bio | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Erin OBoyle | Rezolute | N/A | |
| Michael Deperro | Rezolute | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Harry Lander | Regen BioPharma | 49 | |
| Tumpa Roy | Instil Bio | 52 | |
| Morgan Fields | Rezolute | 36 | |
| Eddie MBA | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Saumyendu Chakrabarti | Instil Bio | 49 | |
| Vojislav Vukovic | Aileron Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 |
Imugene Limited Leadership Team
Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA ASiA, Ex Chairman | ||
| Charles Walker, Non-Executive Director | ||
| Anthony Good, VP Research | ||
| Paul Hopper, Executive Chairman of the Board | ||
| Nathan CA, Joint Sec | ||
| Ursula Wiedermann, Chief Scientific Officer | ||
| PharmD MBA, Chief Officer | ||
| Justyn Stedwell, Joint Company Secretary | ||
| Leslie Chong, CEO, Managing Director | ||
| Ursula McCurry, VP Operations | ||
| Mark Marino, Chief Medical Officer | ||
| Lesley Russell, Non-Executive Director | ||
| Phillip Hains, Joint Company Secretary | ||
| Giovanni Selvaggi, Chief Officer | ||
| ACA BSc, Chief Officer | ||
| Jens Eckstein, Non-Executive Director | ||
| Dr BSc, Chief Officer |
Imugene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Imugene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 737.79 M | |||
| Shares Outstanding | 6.42 B | |||
| Shares Owned By Insiders | 15.40 % | |||
| Shares Owned By Institutions | 8.67 % | |||
| Price To Book | 8.51 X | |||
| Price To Sales | 61.84 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Imugene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Imugene's short interest history, or implied volatility extrapolated from Imugene options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |